印度NATCO公司没有公布其格列卫的晶型,不过从最近一次诺华与印度NATCO在印度的专利官司来看,诺华格列卫试图通过beta晶型的格列卫的功效上的优势来证明其与仿制药的不同,但并没有获得支持。印度NATCO的反击原文是:
‘The present patent specification (of Novartis AG) does not bring out any improvement in the efficacy of the beta-crystal form over the known substances rather it states the base can be used equally in the treatment of diseases or in the preparation of pharmacological agents wherever the beta-crystal is used.’
‘Even the affidavit submitted on behalf of the Applicant (Novartis AG) does not prove any significant enhancement of known efficacy,’ Natco submitted to the Controller.
简单的说就是:beta晶型的格列卫并没有证据表明其能显著提高疗效。另外,印度NATCO公司是在诺华在印度引入格列卫的第二年就引入了仿制格列卫,经过长达十几年的临床使用,应该说已经得到了全世界范围内许多患者的肯定,单从这一点来说,印度格列卫与诺华格列卫几乎无差别。